Veracyte has been generating cash for R&D and striking deals to expand its market reach. Now, the company is touting promising results for its bronchial genomic classifier for lung cancer diagnosis as it takes a deeper dive into the lung cancer testing market.
Navidea Biopharmaceuticalssnagged a $60 million loan to pay down its debt and spur development of its Lymphoseek diagnostic imaging agent, giving the company a boost as it looks to generate international growth for the product. Read more >>
Liquid biopsy tests are gaining traction within the industry as a viable alternative to traditional screening methods for cancer. A recent report by financial services firm Cowen & Co. said annual sales for the tools could surpass $10 billion, and study results are also turning up positive data in favor of the tests. Read more >>
POPULAR COMMENT THREADS
San Diego's Illumina announced that it is filing a patent infringement suit against Roche's Ariosa Diagnostics and its microarray-based Harmony Prenatal Test. The gene sequencing company accuses Ariosa of violating its '794 patent, called "Multiplex Nucleic Acid Reactions."
San Diego's Cypher Genomics has attracted the attention of a biotech legionnaire, teaming up with industry heavyweight Celgene for a companion diagnostics project aimed at uncovering genetic biomarkers that help match patients to a suitable therapy.
MIT and Harvard's collaborative Broad Institute just received a $10 million gift from the Gerstner Family Foundation to conduct research into cancer-resistant drugs using gene-editing technology and blood-based tumor biopsies.
OncoCyte reeled in $7 million in financing to support development of its cancer diagnostic tools, adding fuel to its engine as the company ramps up operations and R&D for its lead products.
Roche got an FDA CLIA waiver for its rapid Strep A test, opening the door to expanded use of the product months after the agency signed off on the test.
Abbott is teaming up with biotech heavyweight AstraZeneca to develop companion diagnostic tests for the company's investigational asthma therapy, a potentially fruitful alliance as Abbott rides the tailwinds of promising diagnostic sales.
From Our Sister Sites
The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.
Boston Scientific revealed more details about its leadless pacemaker program, as it seeks to join Medtronic and St. Jude Medical in that market (which does not yet exist in the U.S., where the devices are still being investigated).